clu / iStockphoto.com
A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha (evolocumab), rejecting a challenge brought by two competitors.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sanofi, Regeneron, Amgen, cholesterol drug, patent infringement, Repatha, US District Court for the District of Delaware